Direct Oral Anticoagulant Therapy: Bleeding Risk Assessment and Management
TMP Universal Journal of Advances in Pharmaceutical Sciences · 08.03.2026 · 2 (1)
DOI: 10.69557/zf6ect41 ↗Kurz gefasst
Fachartikel in der Zeitschrift TMP Universal Journal of Advances in Pharmaceutical Sciences, online erschienen am 08.03.2026. Verfasst von Niranjani C.
Abstract (Originalsprache)
A direct oral anticoagulant is an oral medication that inhibits a specific coagulation factor to prevent thrombus formation. DOACs are primarily used to prevent stroke and systemic embolism in non-valvular atrial fibrillation, to treat and prevent venous thromboembolism, and for postoperative venous thromboembolism prophylaxis in orthopaedic surgery. Anticoagulants prevent thrombus extension and embolic events by decreasing fibrin formation. Anticoagulants do not lyse existing thrombi; rather, they are used to prevent recurrent events. The predictable PK/PD profile, combined with a lower risk of intracranial bleeding compared with vitamin K antagonists, makes direct oral anticoagulants (DOACs) the preferred drugs. However, despite these benefits, there are challenges in clinical practice, including drug interactions, peri-procedural care, and use in patients with renal impairment, hepatic impairment, and cancer. This narrative review supports the safe and effective use of direct oral anticoagulants by evaluating individual bleeding risk factors, using patient-centered strategies for bleeding prevention, monitoring, and management, and highlighting the pharmacist's role in optimizing therapy.
Zitieren
APA
C, N. (2026). Direct Oral Anticoagulant Therapy: Bleeding Risk Assessment and Management. TMP Universal Journal of Advances in Pharmaceutical Sciences, 2(1). https://doi.org/10.69557/zf6ect41
Vancouver
C N. Direct Oral Anticoagulant Therapy: Bleeding Risk Assessment and Management. TMP Universal Journal of Advances in Pharmaceutical Sciences. 2026;2(1). doi:10.69557/zf6ect41
BibTeX
@article{C2026,
author = {C, Niranjani},
title = {Direct Oral Anticoagulant Therapy: Bleeding Risk Assessment and Management},
journal = {TMP Universal Journal of Advances in Pharmaceutical Sciences},
year = {2026},
volume = {2},
number = {1},
doi = {10.69557/zf6ect41}
}
EUVIMED